Search This Blog

Tuesday, April 14, 2026

Praxis Precision Medicines FDA OKs ulixacaltamide NDA for essential tremor, PDUFA Jan 29, 2027

 

Praxis Precision Medicines gets FDA OO on ulixacaltamide NDA for adult essential tremor, PDUFA action date January 29, 2027

  • FDA review will proceed with no advisory committee meeting planned for the ulixacaltamide application.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)